| abstract |
The present invention relates to a method of predicting reaction to Sorafenib treatment using gene polymorphism. More specifically, for the reaction to Sorafenib treatment according to the present invention, it is possible to predict the reaction of a test object to Sorafenib treatment by using an anti-cancer target gene which is expressed in a biological sample of a liver cancer patient as a biomarker, whereby a proper drug is administered to a liver cancer patient and an optimal treatment effect is attained, so that inconvenience of a patient can be reduced, costs for treatment can be reduced, and an individually tailored chemotherapy can more effectively be implemented by administration of a patient-specific anti-cancer agent. |